221 related articles for article (PubMed ID: 28860121)
41. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
42. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
43. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
[TBL] [Abstract][Full Text] [Related]
44. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.
Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066
[TBL] [Abstract][Full Text] [Related]
45. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
46.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
47. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
48. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
49. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract][Full Text] [Related]
50. Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
Hesari Z; Nourbakhsh M; Hosseinkhani S; Abdolvahabi Z; Alipour M; Tavakoli-Yaraki M; Ghorbanhosseini SS; Yousefi Z; Jafarzadeh M; Yarahmadi S
Gene; 2018 Oct; 673():149-158. PubMed ID: 29886033
[TBL] [Abstract][Full Text] [Related]
51. MiR-613 Promotes Cell Death in Breast Cancer Cells by Downregulation of Nicotinamide Phosphoribosyltransferase and Reduction of NAD.
Alizadeh-Fanalou S; Hosseinkhani S; Nazarizadeh A; Ezzati-Mobaser S; Hesari Z; Aziminezhadan P; Abdolvahabi Z; Abolmaali M; Tavakoli-Yaraki M; Nourbakhsh M
DNA Cell Biol; 2021 Jul; 40(7):1026-1036. PubMed ID: 34101492
[TBL] [Abstract][Full Text] [Related]
52. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
53. Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors.
Franco J; Piacente F; Walter M; Fratta S; Ghanem M; Benzi A; Caffa I; Kurkin AV; Altieri A; Herr P; Martínez-Bailén M; Robina I; Bruzzone S; Nencioni A; Del Rio A
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890155
[TBL] [Abstract][Full Text] [Related]
54. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation.
Kraus D; Reckenbeil J; Veit N; Kuerpig S; Meisenheimer M; Beier I; Stark H; Winter J; Probstmeier R
Cell Oncol (Dordr); 2018 Oct; 41(5):485-494. PubMed ID: 29949049
[TBL] [Abstract][Full Text] [Related]
55. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
[TBL] [Abstract][Full Text] [Related]
56. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
57. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Kudo K; Nomura M; Sakamoto Y; Ito S; Morita M; Kawai M; Yamashita Y; Ito K; Yamada H; Shima H; Yaegashi N; Tanuma N
FEBS Lett; 2020 May; 594(9):1379-1388. PubMed ID: 31950503
[TBL] [Abstract][Full Text] [Related]
58. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
59. Properly Substituted Benzimidazoles as a New Promising Class of Nicotinate Phosphoribosyltransferase (NAPRT) Modulators.
Baldassarri C; Giorgioni G; Piergentili A; Quaglia W; Fontana S; Mammoli V; Minazzato G; Marangoni E; Gasparrini M; Sorci L; Raffaelli N; Cappellacci L; Petrelli R; Del Bello F
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259338
[TBL] [Abstract][Full Text] [Related]
60. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
